SCHEMBL3557717

SCHEMBL3557717

COc1cc2cc(C(=O)N3CC(CCl)c4c3cc([N+](=O)[O-])c3cc(C(N)=O)ccc43)[nH]c2c(OC)c1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 1/20 0.46
HSP90AA1 P07900 1/20 0.46
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
POLB P06746 2/20 0.34
MAPT P10636 4/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TP53 P04637 1/20 0.32
HTT P42858 1/20 0.32
RAB9A P51151 1/20 0.32
HRH4 Q9H3N8 1/20 0.31
CTPS1 P17812 1/20 0.31
FBP1 P09467 2/20 0.31
JAK2 O60674 1/20 0.31
ADH1A P07327 1/20 0.31
KIT P10721 1/20 0.31
FLT1 P17948 1/20 0.31
FLT4 P35916 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3561821 0.94 P4HB (0.47) P4HBHSP90AA1KDM4EALDH1A1LMNA
SCHEMBL3557910 0.93 P4HB (0.46) P4HBHSP90AA1KDM4EALDH1A1LMNA
SCHEMBL3559441 0.91 P4HB (0.48) P4HBHSP90AA1KDM4EALDH1A1LMNA
SCHEMBL5624285 0.90 P4HB (0.49) P4HBHSP90AA1KDM4EALDH1A1LMNA
SCHEMBL6205630 0.90 P4HB (0.49) P4HBHSP90AA1KDM4EALDH1A1LMNA
SCHEMBL5623259 0.90 P4HB (0.49) P4HBHSP90AA1KDM4EALDH1A1LMNA
SCHEMBL3557000 0.89 P4HB (0.49) P4HBHSP90AA1KDM4EALDH1A1LMNA
SCHEMBL3569771 0.89 P4HB (0.43) P4HBHSP90AA1KDM4EALDH1A1LMNA
SCHEMBL3560279 0.89 P4HB (0.51) P4HBHSP90AA1KDM4EALDH1A1LMNA
SCHEMBL3569975 0.88 P4HB (0.47) P4HBHSP90AA1KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US claimed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US claimed
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A P4HB 1449/4885HSP90AA1 592/4885KDM4E 856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.